The JUXTAPID® Risk Evaluation and Mitigation Strategy (REMS) Program

A REMS is a strategy to manage known or potential serious risks associated with a drug and is required by the US Food and Drug Administration (FDA) to ensure that the benefits of the drug outweigh its risks.

Aegerion Pharmaceuticals, Inc. (Aegerion) has worked with the FDA to develop the JUXTAPID REMS Program.

The purpose of the JUXTAPID REMS Program is to mitigate the risk of hepatotoxicity associated with the use of JUXTAPID by ensuring that

1. Prescribers are educated about
   - The approved indication for JUXTAPID
   - The risk of hepatotoxicity associated with the use of JUXTAPID
   - The need to monitor patients during treatment with JUXTAPID, as per the product labeling

2. JUXTAPID is dispensed only to patients with a clinical or laboratory diagnosis consistent with homozygous familial hypercholesterolemia

3. Patients are informed about the risk of hepatotoxicity associated with the use of JUXTAPID and the need for baseline and periodic monitoring

Prescriber

All prescribers of JUXTAPID must become certified in the JUXTAPID REMS Program.

The 3-step process for Prescriber Certification is outlined below:

1. Review the JUXTAPID Prescribing Information and the JUXTAPID REMS Program Fact Sheet
2. Complete the online Prescriber Training Module and Prescriber Enrollment Form
3. Agree to counsel each patient using the Patient Guide, and to complete a Patient-Prescriber Acknowledgement Form with each patient

GO TO PRESCRIBER CERTIFICATION

INDICATIONS AND USAGE

Homozygous Familial Hypercholesterolemia

JUXTAPID is indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).

Limitations of Use

- The safety and effectiveness of JUXTAPID have not been established in patients with hypercholesterolemia who do not have HoFH, including those with heterozygous familial hypercholesterolemia (HeFH).
- The effect of JUXTAPID on cardiovascular morbidity and mortality has not been determined.

For additional information about the JUXTAPID REMS Program,
please call 1-855-JUXTAPID (1-855-898-2743)
Pharmacy certification

Prior to beginning certification process, please contact the JUXTAPID REMS Program, 1-855-JUXTAPID (1-855-898-2743) for consideration.

BEGIN NOW

To purchase and dispense JUXTAPID® all pharmacies must be certified in the JUXTAPID Risk Evaluation and Mitigation Strategy (REMS) Program. The pharmacy must identify an Authorized Representative to be certified in the JUXTAPID REMS Program. The pharmacy must be recertified if the authorized person changes.

Pharmacy certification is a 3-step process:

1. Review
   the Prescribing Information and Fact Sheet

2. Complete
   • the online Pharmacy Training Module, including Knowledge Assessment
   • the Pharmacy Enrollment Form
   • Send the Pharmacy Enrollment Form and the Certificate of Completion for the Pharmacy Training Module to the JUXTAPID REMS Coordinating Center by fax: 1-855-898-2498 or email: REMS@aegerion.com

3. Agree
   to train all relevant pharmacy staff, to implement processes and procedures to ensure prescriber certification, to be audited if necessary, and to provide prescription data

For additional information about the JUXTAPID REMS Program, please call 1-855-JUXTAPID (1-855-898-2743)
Prescriber certification

BEGIN NOW

To prescribe JUXTAPID®, healthcare professionals must be certified in the JUXTAPID Risk Evaluation and Mitigation Strategy (REMS) Program.

Prescriber certification is a 3-step process:

1. **Review**
   - the Prescribing Information and Fact Sheet

2. **Complete**
   - the online Prescriber Training Module, including Knowledge Assessment
   - the Prescriber Enrollment Form
   - Send the Prescriber Enrollment Form to the JUXTAPID REMS Coordinating Center by fax: 1-855-898-2498 or email: REMS@aegerion.com

3. **Agree**
   - to counsel each new patient on the risk of hepatotoxicity and the need for baseline and periodic monitoring using the Patient Guide.
   - Complete a Patient-Prescriber Acknowledgement Form with each patient

For additional information about the JUXTAPID REMS Program, please call 1-85-JUXTAPID (1-855-898-2743)
Patient education

Risk of Liver Problems

- JUXTAPID can cause liver problems such as increased liver enzymes or increased fat in the liver.
- Because of the risk of liver problems, JUXTAPID should only be taken by people with homozygous familial hypercholesterolemia (HoFH).
- Your doctor will order blood tests to check your liver before you start taking JUXTAPID, if your dose is increased, and while you are taking JUXTAPID.

The JUXTAPID REMS Program

Because of the risk of liver damage with JUXTAPID, the Food and Drug Administration (FDA) has required a special program called a Risk Evaluation and Mitigation Strategy (REMS).

As part of the REMS Program your prescriber will discuss the risks of JUXTAPID with you, and review the Patient Guide to the REMS Program.

After reviewing the JUXTAPID REMS Program, both you and your healthcare provider will be asked to complete a form acknowledging that you understand the risks with the use of JUXTAPID.

For additional information about the JUXTAPID REMS Program, please call 1-85-JUXTAPID (1-855-898-2743)
For additional information about the JUXTAPID REMS Program, please call 1-85-JUXTAPID (1-855-898-2743)
For additional information about the JUXTAPID REMS Program, please call 1-855-JUXTAPID (1-855-898-2743).
Register

All fields required

First Name: ___________________________ Last Name: ___________________________

Practice name / Pharmacy name: ____________________________________________

City: __________________ State: __________________ ZIP code: ____________

Email: ____________________________

Choose your role:
- Prescriber
- Pharmacy

By clicking "Submit", you agree to the terms in the privacy policy.

Submit
Register

All fields required

First Name: 

Last Name: 

Practice name / Pharmacy name: 

City: 

State: 

ZIP code: 

Email: 

Choose your role:

- Prescriber
- Pharmacy

NPI No.: 

By clicking "Submit", you agree to the terms in the privacy policy.

Submit
The JUXTAPID® Risk Evaluation and Mitigation Strategy (REMS) Program

A REMS is a strategy to manage known or potential serious risks associated with a drug and is required by the US Food and Drug Administration (FDA) to ensure that the benefits of the drug outweigh its risks.

Aegerion Pharmaceuticals, Inc. (Aegerion) has worked with the FDA to develop the JUXTAPID REMS Program.

The purpose of the JUXTAPID REMS Program is to mitigate the risk of hepatotoxicity associated with the use of JUXTAPID by ensuring that:

1. Prescribers are educated about
   - The approved indication for JUXTAPID
   - The risk of hepatotoxicity associated with the use of JUXTAPID
   - The need to monitor patients during treatment with JUXTAPID, as per the product labeling
   - JUXTAPID is dispensed only to patients with a clinical or laboratory diagnosis consistent with homozygous familial hypercholesterolemia
   - Patients are informed about the risk of hepatotoxicity associated with the use of JUXTAPID and the need for baseline and periodic monitoring

Prescriber
All prescribers of JUXTAPID must become certified in the JUXTAPID REMS Program.

The 3-step process for Prescriber Certification is outlined below:

1. Review the JUXTAPID Prescribing Information and the JUXTAPID REMS Program Fact Sheet
2. Complete the online Prescriber Training Module and Prescriber Enrollment Form
3. Agree to counsel each patient using the Patient Guide, and to complete a Patient-Prescriber Acknowledgment Form with each patient

Indications and Usage
Homozygous Familial Hypercholesterolemia
JUXTAPID is indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).

Limited Use

The safety and effectiveness of JUXTAPID have not been established in patients with hypercholesterolemia who do not have HoFH, including those with heterozygous familial hypercholesterolemia (HeFH).

The effect of JUXTAPID on cardiovascular morbidity and mortality has not been determined.

For additional information about the JUXTAPID REMS Program, please call 1-855-JUXTAGUIDE (1-855-878-6284)
Pharmacy certification

Prior to beginning certification process, please contact the JUXTAPID REMS Program, 1-855-JUXTAPID (1-855-898-2743) for consideration.

BEGIN NOW

To purchase and dispense JUXTAPID® all pharmacies must be certified in the JUXTAPID Risk Evaluation and Mitigation Strategy (REMS) Program. The pharmacy must identify an Authorized Representative to be certified in the JUXTAPID REMS Program. The pharmacy must be recertified if the authorized person changes.

Pharmacy certification is a 3-step process:

1. Review the Prescribing Information and Fact Sheet

2. Complete
   - the online Pharmacy Training Module, including Knowledge Assessment
   - the Pharmacy Enrollment Form
   - Send the Pharmacy Enrollment Form and the Certificate of Completion for the Pharmacy Training Module to the JUXTAPID REMS Coordinating Center by fax: 1-855-898-2498 or email: REMS@aegerion.com

3. Agree to train all relevant pharmacy staff, to implement processes and procedures to ensure prescriber certification, to be audited if necessary, and to provide prescription data

Program materials

- Prescribing Information
- Fact Sheet
- Pharmacy Training Module
- Pharmacy Enrollment Form

For additional information about the JUXTAPID REMS Program, please call 1-855-JUXTAPID (1-855-898-2743)
Patient education

Risk of Liver Problems

- JUXTAPID can cause liver problems such as increased liver enzymes or increased fat in the liver.
- Because of the risk of liver problems, JUXTAPID should only be taken by people with homozygous familial hypercholesterolemia (HoFH).
- Your doctor will order blood tests to check your liver before you start taking JUXTAPID, if your dose is increased, and while you are taking JUXTAPID.

The JUXTAPID REMS Program

Because of the risk of liver damage with JUXTAPID, the Food and Drug Administration (FDA) has required a special program called a Risk Evaluation and Mitigation Strategy (REMS).

As part of the REMS Program your prescriber will discuss the risks of JUXTAPID with you, and review the Patient Guide to the REMS Program.

After reviewing the JUXTAPID REMS Program, both you and your healthcare provider will be asked to complete a form acknowledging that you understand the risks with the use of JUXTAPID.

For additional information about the JUXTAPID REMS Program, please call 1-850-JUXTAPID (1-855-898-2743)
Prescriber certification

To prescribe JUXTAPID®, healthcare professionals must be certified in the JUXTAPID Risk Evaluation and Mitigation Strategy (REMS) Program.

Prescriber certification is a 3-step process:

1. Review
   the Prescribing Information and Fact Sheet

2. Complete
   • the online Prescriber Training Module,
     including Knowledge Assessment
   • the Prescriber Enrollment Form
   • Send the Prescriber Enrollment Form to the JUXTAPID REMS Coordinating Center by fax:
     1-855-898-2496 or email:
     REMS@aegerion.com

3. Agree
to counsel each new patient on the risk of hepatotoxicity and the need for baseline and periodic monitoring using the Patient Guide. Complete a Patient-Prescriber Acknowledgement Form with each patient.

Program materials

- PRESCRIBING INFORMATION
- FACT SHEET
- PRESCRIBER TRAINING MODULE
- PATIENT GUIDE AND PATIENT-PREScriber ACKNOWLEDGEMENT FORM
- PRESCRIBER ENROLLMENT FORM
- PRESCRIPTION AUTHORIZATION FORM

For additional information about the JUXTAPID REMS Program, please call 1-855-JUXTAPID (1-855-898-2743)
Sitemap

- Home
- Prescriber Certification
- Pharmacy Certification
- Patient Education
- Privacy Policy
- Terms of Use
- About Aegerion
- Contact Us

Program materials

- Prescribing Information
- Medication Guide
- Fact Sheet
- Prescriber Training Module
- Prescriber Enrollment Form
- Prescription Authorization Form
- Patient Guide and Patient-Prescriber Acknowledgement Form
- Pharmacy Training Module
- Pharmacy Enrollment Form

For additional information about the JUXTAPID REMS Program, please call 1-855-JUXTAPID (1-855-898-2743)
For additional information about the JUXTAPID REMS Program, please call 1-85-JUXTAPID (1-855-898-2743).
Note to Reviewer:

The Juxtapid REMS Pharmacy Training and Knowledge Assessment can be accessed online by clicking the link on the website. The participant will need to register to enter the training and knowledge assessment module. The registration page requires the participant to indicate that they are an authorized representative of the pharmacy.

Participants will be required to enter their name, pharmacy name, city, state and zip code. The participant’s email address will be requested; if this is not provided the participant will be able to continue. These items will be used to generate a Certificate of Completion at the end of the program that will be required to be submitted to enroll the pharmacy in the JUXTAPID REMS program.